
|Articles|February 1, 2004
STAAR Surgical revamps procedures after FDA warning; product complaints at issue
Monrovia, CA-Officials at STAAR Surgical Co. are scrambling to answer questions raised by a warning letter from the FDA that criticized the company for failing to review product complaints adequately and ensure quality control of its manufacturing materials.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
AAO 2025: Philip J. Ferrone, MD, highlights safety and efficacy findings of gildeuretinol in Stargardt disease
2
Preclinical study suggests synaptic regeneration may offer new pathway to treat glaucoma
3
AAO 2025: The evolution of eye care on display at AAO 2025
4
Tensions rise between STAAR and Broadwood as proposed Alcon deal nears vote
5